Novel mutations in the ferritin-L iron-responsive element that only mildly impair IRP binding cause hereditary hyperferritinaemia cataract syndrome
Autor/a
Data de publicació
2013ISSN
1750-1172
Resum
Background: Hereditary Hyperferritinaemia Cataract Syndrome (HHCS) is a rare autosomal dominant disease characterized by increased serum ferritin levels and early onset of bilateral cataract. The disease is caused by mutations in the Iron-Responsive Element (IRE) located in the 5′ untranslated region of L-Ferritin (FTL) mRNA, which post-transcriptionally regulates ferritin expression. Methods: We describe two families presenting high serum ferritin levels and juvenile cataract with novel mutations in the L-ferritin IRE. The mutations were further characterized by in vitro functional studies. Results: We have identified two novel mutations in the IRE of L-Ferritin causing HHCS: the Badalona +36C > U and the Heidelberg +52 G > C mutation. Both mutations conferred reduced binding affinity on recombinant Iron Regulatory Proteins (IPRs) in EMSA experiments. Interestingly, the Badalona +36C > U mutation was found not only in heterozygosity, as expected for an autosomal dominant disease, but also in the homozygous state in some affected subjects. Additionally we report an update of all mutations identified so far to cause HHCS. Conclusions: The Badalona +36C > U and Heidelberg +52 G > C mutations within the L-ferritin IRE only mildly alter the binding capacity of the Iron Regulatory Proteins but are still causative for the disease.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
Anglès
Matèries (CDU)
57 - Biologia
Paraules clau
Pàgines
10
Publicat per
Springer Nature
Col·lecció
8;
Publicat a
Orphanet Journal of Rare Diseases
Citació recomanada
Luscieti, Sara; Tolle, Gabriele; Aranda, Jessica [et al.]. Novel mutations in the ferritin-L iron-responsive element that only mildly impair IRP binding cause hereditary hyperferritinaemia cataract syndrome. Orphanet Journal of Rare Diseases, 2013, 8, 30. Disponible en: <https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-8-30>. Fecha de acceso: 18 ene. 2022. DOI: 10.1186/1750-1172-8-30
Número de l'acord de la subvenció
info:eu-repo/grantAgreement/ES/MINECO/SAF2012-40106
Nota
This work was supported by the grant PS09/00341 from “Instituto de Salud Carlos III”, Spanish Health Program, grant SAF2012-40106 from Ministry of Economy and Competitiveness (MINECO) and grant CIVP16A1857 “Ayudas a proyectos de Investigación en Ciéncias de la Vida Fundación Ramón Areces” to M.S. M.S. held a research contract under the Ramón y Cajal program from the Spanish Ministry of Science and Innovation (RYC-2008-02352). J.A. held a technician support contract under the “Contratos de Técnicos de apoyo a la investigación en el SNS” program from the “Instituto de Salud Carlos III”, Spanish Health Program (CA10/01114). M.U.M. acknowledges funding from the E-RARE/BMBF project 01GM1005 and the Dietmar Hopp Stiftung as well as support from the Center For Rare Diseases, Medical Center University of Heidelberg.
Aquest element apareix en la col·lecció o col·leccions següent(s)
- Ciències de la Salut [973]
Drets
This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/licenses/by/2.0


